☆ 4.8 Meeting Abstract

INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

CANCER RESEARCH (2017)

Get Full Text
Add to Collection

Journal

CANCER RESEARCH
Volume 77, Issue -, Pages -

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1538-7445.AM2017-CT039

Keywords

-

Categories

Oncology

Funding

  1. GlaxoSmithKline
  2. Merck Co, Inc

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.